Significance of various anticoagulation therapies during use of a left ventricular assist device.
A multicomparative study to establish adequate anticoagulation therapy for left ventricular assist devices was undertaken by administrating various anticoagulants: heparin, a prostacyclin analogue combined with a protease inhibitor; thromboxane A2 synthetase inhibitor; or a protease inhibitor alone. Our investigation suggested that combined administration of prostacyclin analogue and protease inhibitor (FUT-175) is ideal anticoagulation therapy from the point of blood coagulation and fibrinolysis. Currently, however, sole administration of FUT-175 is adequate anticoagulation therapy during clinical use of left ventricular assist devices.
Takahama
T
T
First Department of Surgery, Saitama Medical Center, Saitama Medical College, Tokyo, Japan.
Kanai
F
F
Hiraishi
M
M
Onishi
K
K
Yamazaki
Z
Z
Naruse
Y
Y
Furuse
A
A
Yoshitake
T
T
D000925:Anticoagulants / Q000008:administration & dosage*; D001550:Benzamidines; D001780:Blood Coagulation Tests; D005174:Factor XII / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D006146:Guanidines / Q000008:administration & dosage; D006353:Heart-Assist Devices; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D008689:Methacrylates / Q000008:administration & dosage; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010976:Platelet Count / Q000187:drug effects; D000979:alpha-2-Antiplasmin / Q000378:metabolism
D000925:Anticoagulants; D001550:Benzamidines; D006146:Guanidines; D008689:Methacrylates; D010975:Platelet Aggregation Inhibitors; D000979:alpha-2-Antiplasmin; D005174:Factor XII; D005340:Fibrinogen; D006493:Heparin; C034364:ozagrel; C032855:nafamostat